Publications

In this section you will find a list of scientific publications relevant to the IBD community and in which EFCCA has been the co-author.

Early Real-World Outcomes with Filgotinib in Patients with Ulcerative Colitis: A Prospective, Observational Study (GALOCEAN)

Early Real-World Outcomes with Filgotinib in Patients with Ulcerative Colitis: A Prospective, Observational Study (GALOCEAN) October 2024 This study investigates the real-world effectiveness of Filgotinib (FIL), an oral JAK1 preferential inhibitor, in patients with ulcerative colitis (UC). While the clinical efficacy of FIL has been established in the SELECTION trial, real-world data has...

The Impact of Crohn’s Perianal Fistula on Quality of Life: Results of an International Patient Survey

The Impact of Crohn’s Perianal Fistula on Quality of Life: Results of an International Patient Survey August 2023 An international patient survey examined the impact of Crohn’s perianal fistula on patients' quality of life. Patients with both Crohn’s disease and perianal fistulae reported significantly greater negative effects on overall quality of life, well-being, relationships, social...

A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence

A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence November, 2022 The study developed a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Other indicators include, for example, clinical, endoscopic, and biomarker remission, fatigue, and urgency to...

Out‐of‐pocket expenses of patients with inflammatory bowel disease

Out‐of‐pocket expenses of patients with inflammatory bowel disease: a comparison of patient‐reported outcomes across 12 European countries October, 2022 There is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, the study compared patient costs of IBDs between 12 European countries. Read Study...

Paediatric inflammatory bowel disease

Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents September, 2022 The study aims to find potential advanced treatment options for children with inflammatory bowel disease. A 2-day virtual meeting was held on April 14–15, 2021, for multi-stakeholders (clinical academics, patient community, pharmaceutical...

What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease?

What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study September, 2022 As more therapeutic options with their own characteristics become available for inflammatory bowel disease (IBD), drug development and individual treatment decision-making needs to be tailored towards patients'...

Factors associated with medical and psycosocioeconomic changes in IBD during the COVID-19 pandemic and post-pandemic period

Factors associated with medical and psycosocioeconomic changes in IBD during the COVID-19 pandemic and post-pandemic period May, 2021  The pandemic of COVID-19 had posed challenges in every aspect of the people’s life. COVID-19 had affected all age groups in both previously healthy individuals and those with chronic disease including IBD. This study aimed to investigate the occurrence...

Indirect Costs of Inflammatory Bowel Diseases

Indirect Costs of Inflammatory Bowel Diseases July, 2022 The study showed a high relevance of the indirect cost of IBD in the context of economic evaluation, as well as a between-country variability of work-related impairment or informal care. Read Study

A narrative systematic review and categorisation of outcomes in Inflammatory Bowel Disease to inform a Core Outcome Set for real-world evidence

A narrative systematic review and categorisation of outcomes in Inflammatory Bowel Disease to inform a Core Outcome Set for real-world evidence May, 2021 Heterogeneity exists in reported outcomes and outcome measurement instruments (OMI) from observational studies. A core outcome set (COS) for observational and real-world evidence (RWE) in inflammatory bowel disease (IBD) will facilitate...

Anti-SARS-CoV-2 vaccines in IBD

Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey May, 2022 Anti-SARS-CoV-2 vaccines clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease (IBD). The study aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients...